XERS Xeris Biopharma Holdings Inc

$XERS And who remembers $1.2 after the Strongbridge acquisition in 2021 When AC and Brodman were all over us.....Bashing! We hung in there for 5 years! For all of those who blocked me, sorry! IDC. Never forget your Princess, We did prevail, and I knew we would. Lot's more to come. In Celebration of the best investment ever ........🧜‍♀️ Let's Freaking go! XERS!🧜‍♀️🧜‍♀️🧜‍♀️

$XERS I bought this stock in early 2024, and I'm so gad I did. Truly found a gem. This is the largest position in my portfolio. If a buyout takes place anywhere between $25-$40, it will be life-changing for myself and my family. Thanks be to God!

$XERS This is one of the strongest biotechs in a bloody market day, because it is still undervalued. Fair value without even considering XP-8121 right now between $11-$12, everyone can decide what the potential blockbuster XP-8121 is worth to them at the start of phase 3. Swing and accumulate remains our recommendation in this volatile trader's market.

$XERS Wow. This is 10x the price a few years ago when Brodman was bashing and some of us were loading up at 1.05. GL longs! You all deserve it! Special thanks to some of the OGs who did so much research and helped me to understand the potential here.

$XERS - many of us have been here a long time - endured those convertibles, the shorts, and the FUD boys - 5 years ago, we would have sold at $6. We have come a long way and are holding strong! We deserve this and are not selling out!

$XERS Lot's of newbies here now. I go back with the OG's 5 years or so! Just a Beautiful Princess! Congratulations to all! 🧜‍♀️

$XERS All I know is I want the shorts to feel what I felt all of 2022, 2023, and 2024. Is that vindictive? 🥴. Shout out to all my OG's!

$XERS Wow, a dollar a day. I think a few years ago I dreamed about this and even posted about it. Nice.

$XERS Some interesting Dual-hormone pump news from Beta's Q3 review -> Glucagon reformulation completed✔️ Beta Bionics said the drug reformulation for the bi-hormonal system is successfully completed. This is relevant to Xeris because its XeriSol technology provides the glucagon formulation for the exclusive partnership. Additional Phase IIa trials are being prepared. Management said additional Phase IIa trials are in the works. the program is back on track, assuming these trials proceed as planned. Under the exclusive collaboration, Xeris is eligible for development payments + low double digit royalties on future sales of its glucagon for the pump and related systems. *We are talking about development payments and royalties that could generate up to hundreds of millions of dollars in revenue for Xeris if the iLet, the world's only dual-hormone automated insulin&glucagon delivery system, achieves successful commercial growth.

$XERS For the patient investors among you... This chart illustrates the approximate upside potential of Xeris, based on current variables and the revenue opportunities outlined above. If Xeris delivers on this trajectory, it has the potential to become a big pharma company. Of course, Xeris may also develop additional XeriSol-based treatments and drugs in the future, as well as sign exclusive deals with both large and small pharmaceutical companies, as it has done with Beta Bionics, to leverage its XeriSol & XeriJect technologies and molecules. The upside potential of this bio ecosystem seems almost endless. It has the foundations of a big pharma setup - and I can't say the same about my other bio investments. My understanding is that we haven't even scratched the surface of its potential. We're still at the very beginning of the journey... *Keep in mind that Xeris projected only the U.S upside potential for XP-8121. The global market potential is not based on a Xeris projection*

$XERS am anticipating a good report next week, with sales in the neighborhood of $110MM and no write downs ... (all just my opinion of course) which will show a meaningful profit. Thoughts?

$XERS All this talk about the sales force expansion and this is finally the quarter where we should see a significant uptick in Recorlev sales as a result. Really hoping we see at least a 10 mil jump for Recorlev alone. Hoping for another 2-3 million in gains from Keveyis/Gvoke to give us a 12-13 mil jump from last quarter that should put us around 104-105 million for Q3. 1 week to go.

$XERS AI Says: XERS jumped 9.5% intraday, hitting a new 52‑week high of $11.41. The move was driven by raised 2026 revenue guidance and strategic debt retirement, which signals improved financial health and future cash flow confidence. Trading volume was 2.57 million shares, well above normal, showing strong institutional + retail demand. There are also takeover rumors circulating (though the company publicly says it’s not for sale). This combination — better forward guidance, reduced debt, takeover chatter, and a technical breakout — is exactly the kind of cocktail that produces a sharp single‑day pop like the +$0.99 you’re seeing. XERS also hit $11.38–$11.35 in other market feeds today, confirming the breakout. Analysts have recently raised price targets (some up to $16–$18), adding to bullish sentiment. Your XERS is up today because the company materially improved its financial outlook, and the market is rewarding that with a strong rally. The move is news‑driven, not random.

$XERS Times & Perceptions 👁 To be accurate -> Today's revenue-upside thesis is based primarily on assessments published by Xeris management regarding Recorlev and XP-8121. In contrast, the December 30, 2021, assessment was based on the approximate expectations of certain investors. The "problem" today is that very possibly, if we reach ~$60–70 per share by 2030, it could still be far too early to sell. If XP-8121 meets expectations for its target patient population, as the only once-weekly injectable levothyroxine option, it is entirely possible that Xeris could reach a $250-350 valuation per share by 2035, with further growth beyond that... This thing could become a honey trap! Or in other words, you can check out any time you like but you can never leave...

$XERS We need to hear from our old friend ... You have been away too long, so get out from under your bridge and join the group again... We need to start planning for our Vegas Blowout... 👍

$XERS I am going to make a guess that Amgen would enter the bidding war vs Landbeck. Their offer would most likely be an all cash offer and may be north of $20.00! This is going to be a wild day. waiting for algos and short covering to push this to $12 today .

$XERS “If Xeris continues to reject Lundbeck’s acquisition offers, Lundbeck will probably try to accumulate as many shares as possible on the open market by year-end.

$XERS Happy Long weekend OGs. Enjoy your Halloween 🎃, and go out and Vote. - it’s one of the best ways to make it count. Onward and Upward!

$XERS Analyst Sentiment ShiftMultiple firms have raised targets recently:Leerink Partners: $12 → $16 (Outperform) Barclays: $9 → $12 (Overweight) Oppenheimer: Reiterated $18 (Outperform) Consensus rating is now Strong Buy, with an average target of $12.29 and a high target of $18 .

$XERS I just had to close a possiton in the one other company I had stock left in. One bad news and a 73% loss. It was around 13% of my holding.. So the amount was big for me. Xers was the other 87% this time if xers drop after ER I'm throwing what I was left into xers.. Have a nice weekend everyone..